Carl Zeiss Meditec Launches Next-Generation Cirrus 6000 OCT with Enhanced Imaging and Data-Centric Workflow

Carl Zeiss' Cirrus 6000 OCTExamination ProcessNon-invasive throughout，In just a few secondsHigh-definition fundus tomography and vascular images can be obtained., effectively assisting doctors in screening and diagnosing various diseases of the entire eye, while also providing support for surgeries such as cataract and refractive procedures.

High-speed scanning:Adopted high-speed scanning technology, capable of scanning multiple corneal layers per second.Scanning 100,000 times per second, enabling clinicians to achieve in a single scanImaging a larger field of view up to 12 millimeters。

This means that doctors can complete examinations more quickly, reducing patients' waiting time.

# About Carl Zeiss

Carl Zeiss Meditec AG(Stock Code: CZMWY)One of the world's leading medical technology companies, providing innovative technologies and solutions to help doctors improve patients' quality of life.

Founded in 1846, the company is a German enterprise that manufactures optical systems, industrial measuring instruments, and medical devices. It has a presence in various fields of optical equipment, including medical series, binoculars, camera lenses, magnifiers, glasses, and planetariums. To date, it has a glorious history of more than 170 years.

The company operates in approximately 50 countries, with more than 43,000 employees across over 30 production sites, more than 60 sales and service locations, and 30 research and development facilities worldwide.

The company provides includingA complete solution including implants and consumables for the diagnosis and treatment of ophthalmic diseases; innovative visualization solutions in the field of minimally invasive surgery.

Financial report data shows that Carl Zeiss Medical achieved revenue of€2.089 billion (approximately 16.2 billion RMB), compared with 1.903 billion euros in the same period last year,Increased by 9.8%(After adjusting for exchange rate impact: +10.1%),Is the fastest-growing ophthalmic medical device manufacturer globally。

Among them, the revenue of the Ophthalmology strategic business unit increased by 7.3% to reach 1.576 billion euros (approximately 12.2 billion RMB); the revenue of the Microsurgery strategic business unit increased by 18.3% to reach 513 million euros (approximately 4 billion RMB).

April 2024,Carl Zeiss MedicalAnnounce the completion of the valuation of D.O.R.C. (Dutch Ophthalmic Research Center)$1.07 billion (approximately 7.7 billion RMB) acquisition.

The two parties initially announced the acquisition on December 15, 2023. According to the agreement,Carl Zeiss will have a total price of 985 million euros (approximately 1.06 billion US dollars; 7.7 billion RMB), acquiring Dutch ophthalmology company DORC from French investment firm Eurazeo100% equity.